Learn how Akron is changing the ancillary materials industry
Liquid rHu IL-7 and rHu IL-15 coming soon
Our customer support team is standing by
Grow your career with Akron Bio
At Akron, we manufacture high-quality compliant cGMP plasmid DNA for pre-clinical, clinical, and commercial gene therapy and vaccine companies.
Akron offers comprehensive recombinant protein and nuclease development and manufacturing under cGMP compliance. Our approach to developing novel cytokines and gene editing tools is to establish a strong foundation through extensive investigation and optimization, enabling a seamless transition to large-scale production.
Capitalizing on our established platform for manufacturing cGMP-compliant, clinical-grade ancillary products, Akron is well-positioned to provide custom development and manufacturing to accelerate the commercialization of advanced therapies.
We offer cGMP-compliant viral transduction enhancers and non-viral transfection reagents and solutions to enable your therapeutic programs’ success. We offer flexible filling capabilities and several manufacturing environments to meet your needs.
Akron’s high-quality cGMP Recombinant Proteins offer the consistency, safety, and efficacy that empower today’s leading clinical and commercial cell therapy companies.
Akron’s proven blood products deliver safety and performance backed by robust and redundant supply. Because you can’t afford to compromise.
We offer critical media and media supplements in both cGMP and high-quality research grade.
Our CSS product line is available in single-use, ready-to-use bags with weldable tubing to ensure consistency and sterility. This product line was developed to integrate optimally dosed, cGMP-compliant blood-derived products and liquid cytokines across manufacturing platforms.
Jan 17, 2023
Akron Bio Receives Eligibility Confirmation from PMDA in Japan for the Commercialization of Virus Inactivated Human Fibronectin in Clinical Cell Therapy Manufacturing
Oct 28, 2022
Meeting the Increasing Manufacturing Demands of the Rapidly Growing Cell and Gene Therapy and Vaccine Markets, Upcoming Webinar Hosted by Xtalks
Our team will be in London from February 27 - 29 to participate in Hanson Wade's CAR-TCR Europe Summit. Sara Padrell, PhD will be presenting on "The evolution and standardization of ancillary materials for the industrialization and democratization of cell-based immunotherapies" at this year's event. If you want to learn more about our product and service offerings, attend her presentation or connect with a member of our team.
Our business development team will be in Boston from March 5 - 7, 2024 to attend the DNA Process Development & Manufacturing Summit. Reach out to a member of our team to learn about our product and service offerings.
San Diego, CA
We will be exhibiting at the Innate Killer Summit from March 18 - 20! Stop by our booth to learn how our products and service offerings can support your cell therapy programs. We hope to see you there!
We are heading to London to attend Terrapin's Advanced Therapies conference. Reach out to a member of our business development team to learn about our product and service offerings.
Our team will be at this year's Meeting on the Med in Rome, Italy from April 9 - 11. Connect with one of our team members to learn how our products and service offerings can support your Advanced Therapies.
Our European Business Development Director, Sara Padrell is attending the CRISPR Medicine Conference in Denmark! Connect with her to learn how our plasmid DNA and gene-editing nuclease development and manufacturing services can support your Advanced Therapies. We hope to see you there!